JP2024502469A5 - - Google Patents

Info

Publication number
JP2024502469A5
JP2024502469A5 JP2023541510A JP2023541510A JP2024502469A5 JP 2024502469 A5 JP2024502469 A5 JP 2024502469A5 JP 2023541510 A JP2023541510 A JP 2023541510A JP 2023541510 A JP2023541510 A JP 2023541510A JP 2024502469 A5 JP2024502469 A5 JP 2024502469A5
Authority
JP
Japan
Prior art keywords
optionally substituted
pharmaceutically acceptable
acceptable salt
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011560 external-priority patent/WO2022150555A2/en
Publication of JP2024502469A publication Critical patent/JP2024502469A/ja
Publication of JP2024502469A5 publication Critical patent/JP2024502469A5/ja
Pending legal-status Critical Current

Links

JP2023541510A 2021-01-08 2022-01-07 フリードライヒ運動失調症を治療するための方法及び化合物 Pending JP2024502469A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135427P 2021-01-08 2021-01-08
US63/135,427 2021-01-08
PCT/US2022/011560 WO2022150555A2 (en) 2021-01-08 2022-01-07 Methods and compounds for treating friedreich's ataxia

Publications (2)

Publication Number Publication Date
JP2024502469A JP2024502469A (ja) 2024-01-19
JP2024502469A5 true JP2024502469A5 (enExample) 2025-01-09

Family

ID=82358799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541510A Pending JP2024502469A (ja) 2021-01-08 2022-01-07 フリードライヒ運動失調症を治療するための方法及び化合物

Country Status (11)

Country Link
US (1) US20240124491A1 (enExample)
EP (1) EP4274583A4 (enExample)
JP (1) JP2024502469A (enExample)
CN (1) CN117241805A (enExample)
AR (1) AR124589A1 (enExample)
AU (1) AU2022206424A1 (enExample)
CA (1) CA3204523A1 (enExample)
IL (1) IL304322A (enExample)
MX (1) MX2023008153A (enExample)
TW (1) TW202241892A (enExample)
WO (1) WO2022150555A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117241805A (zh) * 2021-01-08 2023-12-15 设计治疗公司 用于治疗弗里德希氏共济失调的方法和化合物
TW202334148A (zh) * 2022-01-06 2023-09-01 美商規劃醫療公司 用於治療弗里德希氏共濟失調(friedreich's ataxia)之化合物及方法
WO2025067451A1 (zh) * 2023-09-27 2025-04-03 北京沐华生物科技有限责任公司 一类brd4蛋白降解剂化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270727A1 (en) * 2005-05-03 2006-11-30 Christian Melander Small molecule therapeutics and uses therefor
WO2015074081A1 (en) * 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
GB201504314D0 (en) * 2015-03-13 2015-04-29 Univ Dundee Small molecules
ES3037659T3 (en) * 2016-03-30 2025-10-03 Wisconsin Alumni Res Found Methods and compositions for modulating frataxin expression
ES2793239T3 (es) * 2016-04-15 2020-11-13 Abbvie Inc Inhibidores del bromodominio
US20210283265A1 (en) * 2018-04-20 2021-09-16 Design Therapeutics, Inc. Methods and compounds for the treatment of genetic disease
WO2019226836A1 (en) * 2018-05-22 2019-11-28 Design Therapeutics Inc. Methods and compounds for the treatment of genetic disease
WO2020056188A1 (en) * 2018-09-12 2020-03-19 Board Of Regents, The University Of Texas System Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer
EP4100404A4 (en) * 2020-02-03 2024-05-22 Design Therapeutics, Inc. METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASES
CN117279636A (zh) * 2020-12-11 2023-12-22 设计治疗公司 用于调节强直性肌营养不良1型的方法和化合物
CN117241805A (zh) * 2021-01-08 2023-12-15 设计治疗公司 用于治疗弗里德希氏共济失调的方法和化合物

Similar Documents

Publication Publication Date Title
JP2023011074A5 (enExample)
JP2023516886A5 (enExample)
JP2022533069A5 (enExample)
RU2190594C2 (ru) Органические нитраты и фармацевтическая композиция, обладающая ингибирующей агрегацию тромбоцитов активностью, на их основе
JP2023554317A5 (enExample)
JP2020513019A5 (enExample)
JP2024532465A5 (enExample)
JP2024521757A5 (enExample)
JP2022518210A5 (enExample)
JP2015531789A5 (enExample)
EP3463293A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, une insuline prandiale et/ou une hormone gastrointestinale, et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JP2015091868A5 (enExample)
JP2023513658A5 (enExample)
RU2009122582A (ru) Пэг-модифицированный эксендин или аналог эксендина и его композиции и применение
JP2024542188A5 (enExample)
JPWO2021049504A5 (enExample)
JP2025512877A5 (enExample)
JP2017529322A5 (enExample)
PT1322597E (pt) Processo e intermediários
JP2022533991A5 (enExample)
JP2008504237A5 (enExample)
JP2020514299A5 (enExample)
JP2022539091A5 (enExample)
JP2020511450A5 (enExample)
JP2025509134A5 (enExample)